E-therapeutics Regulatory News (ETX)

e-Therapeutics plc

('e-Therapeutics' or 'the Company')

Share price movement

26 February 2015, Oxford and Newcastle, UK: e-Therapeutics plc (AIM: ETX), the drug discovery and development company, notes the recent rise in its share price and confirms the following.

The Company has continued to observe high levels of productivity through the application of its proprietary drug discovery processes, finding a large number of highly active molecules in cellular screens for molecules selected by the discovery platform, as was noted in the RNS issued on 27 November 2014.

e-Therapeutics believes that this yield of active compounds represents a proportion of those screened that is several orders of magnitude higher than the published ranges observed in conventional drug discovery processes. The Company believes this enrichment reflects the utility of using its proprietary approach to network science and chemical biology to enhance the selection of molecules that are likely to be attractive for further development. The Company continues to focus its discovery team on generating a substantial number of strong candidate molecules across several disease areas.

Discovery and development activity at the Company otherwise continues in line with stated plans and the Company intends to provide a further update in its full year results for the year ended January 2015, expected to be released on 31 March 2015.

-Ends-

Contacts:

e-Therapeutics plc

Steve Medlicott

Tel: +44 (0) 1993 883125

www.etherapeutics.co.uk 

N+1 Singer LLP

Aubrey Powell / Jen Boorer

Tel: +44 (0)20 7496 3000

www.n1singer.com 

Instinctif Partners

Melanie Toyne-Sewell / Emma Barlow

Tel: +44 (0) 20 7457 2020

Email: e-therapeutics@instinctif.com

About e-Therapeutics plc

e-Therapeutics is an AIM-quoted drug discovery and development company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company's discovery and development activity is currently focused in cancer and disorders of the nervous system.

e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company, please visit www.etherapeutics.co.uk.